Forty Seven initiated with a Buy at BTIG. BTIG analyst Robert Hazlett started Forty Seven with a Buy rating and $36 price target. The company develops therapeutics based on the “transformational discovery” of CD47 as a novel immune pathway that controls signals that cells send to macrophages, Hazlett tells investors in a research note. The analyst believes blocking CD47 signaling has the potential to enable and enhance anti-cancer macrophage activity, as well as incremental adaptive immune responses, leading to potential broad anti-cancer activity for anti-CD47 approaches.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.